Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylprednisolone liposomal - EnhanX Biopharm

Next Previous
Drug Profile

Methylprednisolone liposomal - EnhanX Biopharm

Alternative Names: 2B3-201; Brain-targeted methylprednisolone - 2-BBB Medicines; ENX-201; Glutathione PEGylated-liposomal methylprednisolone - 2-BBB Medicines

Latest Information Update: 28 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator to-BBB technologies
  • Developer 2-BBB Medicines
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antirheumatics; Glucocorticoids; Pregnadienetriols
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported CNS disorders; Multiple sclerosis

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for phase-I development in Multiple-sclerosis in Netherlands (IV, Liposomal)
  • 23 Jan 2020 Pharmacodynamics data from a preclinical study in Multiple sclerosis presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 24th Annual Conference of Rehabilitation in MS (ECTRIMS-2019)
  • 11 Sep 2019 Clinical development is still ongoing for Multiple sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top